Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive skin tumor, and its origin from a burn scar is extremely rare. We report a case of a man in his 60s with DFSP that arose within an electrical burn scar sustained from electrical defibrillation for cardiac arrhythmia 20 years prior. The patient presented with a pedunculated tumor and a nearby subcutaneous nodule on his anterior chest. The diagnosis of DFSP was confirmed by histopathological examination, which revealed a characteristic storiform proliferation of spindle cells, and by immunohistochemistry showing positivity for CD34 and negative for epithelial membrane antigen (EMA), S-100, and alpha-smooth muscle actin (α-SMA). Wide local excision and reconstruction with a latissimus dorsi myocutaneous flap and a split-thickness skin graft were performed. The patient has shown no evidence of recurrence for two years postoperatively. As demonstrated by the subcutaneous nodule in this case, DFSP can be clinically difficult to diagnose. Therefore, careful long-term follow-up and consideration of a skin biopsy, as needed, are crucial for such burn scars.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366674 | PMC |
| http://dx.doi.org/10.7759/cureus.88438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan-lysyl oxidase inhibitor PXS-6302 in mature scars.
Sci Transl Med
September 2025
Burn Injury Research Unit, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia 6009, Australia.
Skin scars remain a substantial clinical challenge because of their impact on appearance and psychological well-being. Lysyl oxidases catalyze collagen cross-linking, a key factor in scar development. Here, we report a randomized, double-blind, placebo-controlled phase 1 study to assess the safety and tolerability of PXS-6302, a topical pan-lysyl oxidase inhibitor, in treating mature scars (ACTRN12621001545853).
View Article and Find Full Text PDFThe ferroptosis-associated gene TIMP1 facilitates skin scar formation through the interaction with CST3 in fibroblasts.
Int Immunopharmacol
September 2025
Medical Center of Burn Plastic and Wound Repair, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi, China. Electronic address:
Skin scar formation is a critical pathological process in wound healing, but its underlying regulatory mechanisms remain incompletely elucidated. By integrating analyses of Bulk-RNA seq and single-cell RNA sequencing (scRNA-seq) data, we identified that ferroptosis-related biological processes potentially play a key role in skin scar formation. Further mechanistic studies demonstrated that in human dermal fibroblast cells, the ferroptosis regulator TIMP metallopeptidase inhibitor 1 (TIMP1) significantly promotes fibroblast differentiation toward a mature phenotype through interactions with cystatin C (CST3), characterized by upregulated expression of myofibroblast differentiation markers such as α-smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF), along with enhanced cell proliferation and migration abilities.
View Article and Find Full Text PDFSuccessful treatment of disfiguring facial scar using surgery combined with superficial radiotherapy: a case report with literature review.
Front Oncol
August 2025
Institute of Burns, Tongren Hospital of Wuhan University and Wuhan Third Hospital, Wuhan, China.
Introduction: Facial scars are generally disfiguring and can cause both physiological and psychological trauma. Currently, there is a lack of effective treatment options for facial scars. In recent years, local superficial radiation therapy has emerged as a clinically proven treatment to effectively prevent scar recurrence after surgery.
View Article and Find Full Text PDFLocked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF.
Front Pharmacol
August 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China.
Connective tissue growth factor (CTGF) is notably upregulated in scar tissue, making it a promising target for therapeutic intervention. Here, we have designed and screened an antisense oligonucleotide (ASO) that binds specifically to the exon five sequence of CTGF, with particular emphasis on the use of 2'-O-methoxyethyl (MOE) and locked nucleic acid (LNA) modifications to enhance stability and specificity. experiments demonstrated that both MOE-ASO#1 and LNA-ASO#1 significantly inhibited fibroblast proliferation and extracellular matrix protein expression.
View Article and Find Full Text PDFCell-free adipose extract inhibits hypertrophic scar formation through collagen remodeling and antiangiogenesis.
Open Med (Wars)
August 2025
Department of Burns and Wound Repair, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Objective: Hypertrophic scars (HS) are a fibrotic proliferative disorder that results from an abnormal wound healing process, presenting significant challenges for clinical intervention. The primary characteristics of HS include excessive collagen deposition and angiogenesis. In recent years, the study of mesenchymal stem cells (MSCs) and their derived exosomes has emerged as a prominent area of research within the academic community.
View Article and Find Full Text PDF